A committee of international experts under the auspices of the International Atomic Energy Agency (IAEA), in cooperation with the EANM Therapy, Oncology and Dosimetry Committees and with the Society of Nuclear Medicine and Molecular Imaging, worked together to create this guidance document on the use of somatostatin analogue-based PRRNT. This 120 page guidance document released in February 2013, was compiled taking into account recent literature and experts’ opinion and can be downloaded here. An summary of the guide was also published in the European Journal of Nuclear Medicine and Molecular Imaging.


The authors of this international guide are: John J. Zaknun, L. Bodei, J. Mueller-Brand, M. E. Pavel, R. P. Baum, D. Hörsch, M. S. O’Dorisio, T. M. O’Dorisiol, J. R. Howe, M. Cremonesi, and D. J. Kwekkeboom